A total of 105 head sold for $8,620,500, with an average of $81,325 and a median of $47,500. The median and average were up ...
Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...
Zacks.com on MSN6h
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study DataAs the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...
Researchers from VIB and VUB now provide an interactive tool, based on a single-cell RNA-sequencing (scRNA-seq) atlas of the ...
Gene mutations have consequences both good and bad—from resistance to conditions like diabetes to susceptibility to certain ...
Zymo’s Quick DNA/RNA Viral MagBead Kit was automated using Analytik Jena’s Cybio FeliX pipetting robot. The CyBio FeliX ...
Hosted on MSN10h
RNA Stock Hits Record High on Entering the Cardiac Disease SpaceShares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...
Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...
At TED AI 2024 in October, one of those eight researchers, Jakob Uszkoreit, spoke with Ars Technica about the development of ...
Efforts, both nationally and local, have been made to improve the treatment of sepsis. Last year Gov. Dan McKee signed a law ...
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on RNA stock, giving a Buy rating yesterday. Joseph Schwartz has given his Buy rating due to a combination of factors that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback